KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Operating Margin (2016 - 2026)

TherapeuticsMD filings provide 16 years of Operating Margin readings, the most recent being 99.86% for Q1 2026.

  • On a quarterly basis, Operating Margin rose 22609.0% to 99.86% in Q1 2026 year-over-year; TTM through Mar 2026 was 114.29%, a 20380.0% increase, with the full-year FY2025 number at 145.27%, up 20181.0% from a year prior.
  • Operating Margin hit 99.86% in Q1 2026 for TherapeuticsMD, up from 173.8% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 70.65% in Q4 2022 to a low of 4269.25% in Q2 2022.
  • Median Operating Margin over the past 5 years was 325.95% (2025), compared with a mean of 1081.72%.
  • Biggest five-year swings in Operating Margin: plummeted -411631bps in 2022 and later skyrocketed 370358bps in 2023.
  • TherapeuticsMD's Operating Margin stood at 70.65% in 2022, then plummeted by -554bps to 320.92% in 2023, then skyrocketed by 70bps to 97.75% in 2024, then crashed by -78bps to 173.8% in 2025, then skyrocketed by 43bps to 99.86% in 2026.
  • The last three reported values for Operating Margin were 99.86% (Q1 2026), 173.8% (Q4 2025), and 109.95% (Q3 2025) per Business Quant data.